IPO

The water midstream leader's inaugural dividend signals financial confidence, but a look at its balance sheet reveals a complex picture of growth and debt.

Fintech giant Chime forecasts its first full year of GAAP profitability in 2026, propelled by its new ChimeCore platform, AI, and strong product growth.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

With record revenue and key battery tech milestones met, Enovix is on the brink of powering smartphones, but manufacturing hurdles and cash burn remain.

With $125 million in hand, ClearThink 1 enters a recovering SPAC market, setting its sights on a transformative deal in the dynamic financial services sector.

From a Bitcoin Runes asset to a decentralized AI network, Crypto Burger's new direction aims to unlock Bitcoin's programmable future after its Gate.io listing.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

A private market index tracking tech giants like SpaceX surged nearly 200% in 14 months, raising questions about a new, exclusive tier of wealth creation.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Amid a volatile market, Rock Tech Lithium's latest funding from existing investors signals strong confidence in its strategy to build a local battery supply chain.

With new CFO and Exploration SVP, Goldsky Resources signals a major push to develop its newly consolidated Swedish and Finnish gold and cobalt assets.

Hawaiian beverage company Waiākea rolls out the world's first carbon-negative algae ink on its bottles, an open-source move to transform the industry.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

With legendary geologist Doug Kirwin and Latin America expert Carlos Velásquez on board, Terra Rossa is set to unlock its high-grade Vetas gold project.

Empire Petroleum expands its capital raise and extends the deadline, backed by its largest shareholder in a significant vote of confidence for its growth plans.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

In its first report as a public company, Medline posts $28.4B in annual sales but faces declining net income from tariffs and IPO costs.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.